Mindray Medical International Limited (MR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Mindray Medical International Limited MR, headquartered in Shenzhen, China, commenced operations in 1991. The company conducts much of its business through its consolidated operating subsidiary, Shenzhen Mindray, which was established in 1999. Mindray owns about 99.9% of the equity of Shenzhen Mindray. It maintains its global operational headquarters (HQ) in Shenzhen while the U.S. HQ is in Mahwah, New Jersey.

Mindray is a developer, manufacturer and seller of medical devices globally. It has three segments, namely Patient Monitoring and Life Support products, In-Vitro Diagnostic products and Medical Imaging Systems.

Mindray's largest segment, Patient Monitoring and Life Support (38.7% of total revenues in 2013), includes products such as patient monitoring devices PMD, anesthesia devices, defibrillators, surgical lights, and beds. Generally, PMDs measure real-time, concurrent, or dynamic physiological parameters such as heart rate, blood pressure, respiration, and temperature. In China, the company is the leading player in the patient monitoring market.

The In-Vitro Diagnostics segment or IVD (27.6%) includes products in 5 instrument categories used for diagnostic testing: hematology analysis products, biochemistry analysis products, urine sediment analysis products, microbiology analysis products and coagulation analysis products. In addition, the company manufactures and sells over 150 separate reagents for both hematology and biochemistry analyzers. Reagents are a major source of recurring revenue.

The Medical Imaging Systems segment (25.0%) includes the following product lines: black and white ultrasound, color ultrasound, and digital radiography. Historically, this product segment has consisted primarily of portable and mobile ultrasound systems.

The Others segment (8.7%) derives revenues from provision of after-sales services along with research and development services performed for original design manufacturers (ODM). This segment also includes revenues from acquired business, such as orthopedic products, endoscope devices and healthcare IT solutions products that are outside the other three business segments.

Mindray sells products through different distribution channels in various parts of the world. In the U.S., U.K., France, Germany and the Netherlands, the company sells its products through a direct sales model. In China, it sells its goods mainly to third-party distributors. It had one of the largest distribution and sales networks for medical devices in that country with over 1,300 distributors and about 1,900 sales and sales support personnel. Outside China, Mindray marketed its products through more than 1,500 third-party distributors and its sales force of about 900 people. In 2013, revenues from China accounted for 45.4% of the company's total revenues and revenues from international operations accounted for 54.6% of the company's total revenues.

The company ensured after-sales service to distributors and hospitals in China through local offices. It also provides after-sales service for medical facilities based in the U.S., the U.K., France and Germany. The company extends after-sales care for its other international customers through its distribution channels.

Mindray maintains R&D facilities in Shenzhen, Beijing, Nanjing, Chengdu, Xi'An and Shanghai in China. The company runs R&D operations in Seattle, Washington, Mahwah, New Jersey, Stockholm, Sweden and Miami, Florida. It manufactures the majority of its products at its three plants located in Shenzhen, and one facility in Nanjing, China. Mindray also assembles and stores a number of products at its Mahwah, New Jersey facility.